Evidence map›Paper›PMID 42438219›Full record

ArticleBritish journal of haematology2026

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Michael WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9748-5486
Wojciech JurczakDepartment of Clinical Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland.
Marek TrnenyFirst Department of Internal Medicine - Hematology, General University Hospital in Prague, Prague, Czech Republic.ORCID https://orcid.org/0000-0002-6952-6073
David Belada4th Department of Internal Medicine - Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
Tomasz WrobelDepartment of Medicine, Wrocław Medical University, Wrocław, Poland.ORCID https://orcid.org/0000-0002-6612-3535
Nilanjan GhoshDepartment of Hematology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.ORCID https://orcid.org/0000-0002-3848-6136
Mary-Margaret KeatingDivision of Hematology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
Tom van MeertenDepartment of Hematology, Universitair Medisch Centrum Groningen, Groningen, the Netherlands.ORCID https://orcid.org/0000-0002-5581-6950
Ruben Fernandez AlvarezDepartment of Hematology, Hospital Universitario de Cabueñes, Asturias, Spain.
Gottfried von KeudellDepartment of Internal Medicine - Hematology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Catherine ThieblemontUniversité Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-oncologie, Paris, France.
Frederic PeyradeDepartment of Onco-Hematology, Centre Hospitalier Simone Veil, Cannes, France.
Marc AndreDepartment of Hematology, CHU UCL Namur Mont-Godinne, Yvoir, Belgium.
Marc HoffmannDepartment of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas, USA.
Edith Szafer-GlusmanPrecision Medicine Oncology, AbbVie, North Chicago, Illinois, USA.
Jennifer LinBiostatistics, AbbVie, North Chicago, Illinois, USA.
James P DeanOncology Clinical Development, AbbVie, North Chicago, Illinois, USA.
Jutta K NeuenburgOncology Clinical Development, AbbVie, North Chicago, Illinois, USA.
Constantine S TamPeter MacCallum Cancer Centre, Alfred Health and Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-9759-5017

Funding

AbbVieJanssen Research and Development
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ibrutinibmantle cell lymphomavenetoclax

Identifiers

PMID42438219
PMCPMC13462179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.